BPTH 最新10-Q变化
将 BPTH 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-20 与上一份 10-Q · 2026-01-13
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +9 | −24 | ~13 | 44 |
| 控制与程序 | 无段落级文字变化 | 0 | 0 | 0 | 3 |
| 风险因素 | 无段落级文字变化 | 0 | 0 | 0 | 2 |
| 其他信息 | 文字有新增/删除 | +1 | 0 | 0 | 6 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Net cash used in operating activities for the three months ended March 31, 2025 was $1.3 million. Excluding non-cash change in fair value of the warrant liability of $0.4 million and stock-based compensation expense of $0.1 million,. net cash used in operating activities for the three months ended M…
Net cash provided by financing activities for the three months ended March 31, 2025 was $0.3 million from the Warrant Exercises and the March 2025 Promissory Notes (each as defined below). Net cash provided by financing activities for the three months ended March 31, 2024 was $0.2 million from the M…
As of March 31, 2026, the March 2025 Promissory Notes and April 2025 Promissory Note were in default and became convertible under the default provisions.
On December 29. 2025, the Company entered into a securities purchase agreement with Vanquish Funding Group, Inc. (the “Third Lender” and together with the First Lender and Second Lender, the “Lenders”),, an accredited investor, for the issuance and sale of a promissory note in the aggregate principa…
On January 2, 2026, the Company entered into a securities purchase agreement with the Second Lender. (together with the First Lender, Second Lender and Third Lender, the “Lenders”),, an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $38,500 (…
相对上期删除的文字 · 来源:10-Q · 2026-01-13
Comparisons of the Nine Months Ended September 30, 2025 to the Nine Months Ended September 30, 2024
Revenue. We had no revenue for each of the nine months ended September 30, 2025 and 2024.
Research and Development Expense. Our research and development expense for the nine months ended September 30, 2025 was $6.3 million, an increase of $0.8 million compared to the nine months ended September 30, 2025. The increase in research and development expense was primarily due to expenses relat…
General and Administrative Expense. Our general and administrative expense for the nine months ended September 30, 2025 was $2.0 million, a decrease of $1.9 million compared to the nine months ended September 30, 2024. The decrease in general and administrative expense was primarily due to decreased…
Net Operating Loss. Our net loss from operations for the nine months ended September 30, 2025 was $8.3 million, a decrease of $1.1 million compared to the nine months ended September 30, 2024.
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-20
On November 13, 2025, the Company accepted the resignation of Doug Morris from the Board of Directors
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议